BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BIOGEN INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$233.48+0.83 (+0.36%)
Close on Oct 19, 2026
- Market cap
- $34.72B
- P/E (TTM)
- 41.3
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
96.3%
142M of 148M shares
Institutional holders
1,041
126 new, 83 sold out
Net institutional buying
7M
In Q2 2026
Insider trades, 12 months
1 buys · 4 sales
Net sold $904.83K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| State Street Corporation | 7,321,168 | 5.00% | 13G (passive) | Sep 30, 2025 |
| Abigail P. Johnson | 18,294,524 | 12.40% | 13G (passive) amendment | Jun 30, 2026 |
| FMR LLC | 16,652,975 | 11.30% | 13G (passive) amendment | May 29, 2026 |
| Primecap Management Co/Ca/ | 14,954,697 | 10.20% | 13G (passive) amendment | Sep 30, 2025 |
| BlackRock, Inc. | 12,506,681 | 8.50% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 10,989,562 | 7.48% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BIIB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 18,217,239 | 12.33% | $3.94B | +5,409,698 | 0.17% |
| BlackRock, Inc. | 15,985,736 | 10.82% | $3.45B | +11,135 | 0.05% |
| Primecap Management Co/Ca/ | 15,154,606 | 10.26% | $3.27B | +396,999 | 1.94% |
| Vanguard Capital Management LLC | 9,651,117 | 6.53% | $2.09B | +113,700 | 0.04% |
| State Street Corp | 7,344,327 | 4.97% | $1.59B | +176,405 | 0.05% |
| Vanguard Portfolio Management LLC | 6,604,936 | 4.47% | $1.43B | +73,209 | 0.06% |
| Geode Capital Management, LLC | 4,449,295 | 3.01% | $957.94M | +106,693 | 0.05% |
| Wellington Management Group Llp | 3,117,469 | 2.11% | $673.56M | +155,828 | 0.12% |
| Norges Bank | 2,580,033 | 1.75% | $557.44M | New | 0.06% |
| Morgan Stanley | 2,411,271 | 1.63% | $520.98M | +240,331 | 0.03% |
| Aqr Capital Management LLC | 1,936,859 | 1.31% | $416.93M | +13,302 | 0.15% |
| JPMorgan Chase & Co | 1,823,140 | 1.23% | $394.95M | −192,869 | 0.02% |
| Invesco Ltd. | 1,803,944 | 1.22% | $389.76M | +58,689 | 0.03% |
| Amundi | 1,516,831 | 1.03% | $327.73M | +726,004 | 0.08% |
| Legal & General Group Plc | 1,493,289 | 1.01% | $322.64M | +143,457 | 0.07% |
| Northern Trust Corp | 1,429,490 | 0.97% | $308.86M | −17,089 | 0.04% |
| Boston Partners | 1,263,429 | 0.86% | $272.85M | −436,649 | 0.24% |
| UBS Asset Management Americas Inc | 1,255,168 | 0.85% | $271.19M | −122,400 | 0.05% |
| Goldman Sachs Group Inc | 1,230,390 | 0.83% | $265.84M | +179,296 | 0.02% |
| Dimensional Fund Advisors LP | 1,148,568 | 0.78% | $248.17M | +69,449 | 0.04% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,041 | 142M | 96.3% | 126 / 426 | 293 / 83 | 16M | 9M |
| Q1 2026 | 1,012 | 135M | 91.3% | 137 / 401 | 291 / 107 | 28M | 16M |
| Q4 2025 | 1,001 | 141M | 95.5% | 190 / 322 | 299 / 81 | 22M | 13M |
| Q3 2025 | 908 | 133M | 89.8% | 124 / 323 | 269 / 74 | 13M | 11M |
| Q2 2025 | 867 | 131M | 88.4% | 96 / 342 | 264 / 100 | 13M | 12M |
| Q1 2025 | 882 | 130M | 87.9% | 125 / 331 | 274 / 106 | 10M | 13M |
| Q4 2024 | 876 | 133M | 89.7% | 132 / 299 | 323 / 159 | 17M | 19M |
| Q3 2024 | 918 | 135M | 91.5% | 101 / 271 | 378 / 118 | 26M | 10M |
| Q2 2024 | 944 | 134M | 90.6% | 101 / 323 | 336 / 97 | 8M | 12M |
| Q1 2024 | 953 | 138M | 93.3% | 105 / 302 | 355 / 146 | 12M | 10M |
| Q4 2023 | 1,003 | 136M | 92.0% | 136 / 286 | 376 / 81 | 18M | 7M |
| Q3 2023 | 965 | 125M | 84.8% | 91 / 333 | 346 / 119 | 8M | 8M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of BIIB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Primecap Fund | 8,359,880 | 5.66% | $1.81B | 1.88% | Jun 30, 2026 |
| Fidelity Contrafund | 4,988,655 | 3.38% | $1.08B | 0.60% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,687,985 | 3.17% | $1.01B | 0.04% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 3,827,862 | 2.59% | $827.05M | 0.05% | Jun 30, 2026 |
| Vanguard Mid-Cap Index Fund | 3,199,078 | 2.17% | $691.19M | 0.31% | Jun 30, 2026 |
| Vanguard Health Care Fund | 2,745,486 | 1.86% | $557.20M | 1.46% | Jul 31, 2026 |
| Vanguard Capital Opportunity Fund | 2,624,317 | 1.78% | $567.01M | 1.73% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 2,031,041 | 1.37% | $438.83M | 0.05% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 2,027,406 | 1.37% | $397.37M | 0.16% | May 31, 2026 |
| Fidelity 500 Index Fund | 1,878,080 | 1.27% | $368.10M | 0.04% | May 31, 2026 |
| Vanguard Value Index Fund | 1,403,950 | 0.95% | $303.34M | 0.12% | Jun 30, 2026 |
| Vanguard Primecap Core Fund | 1,316,936 | 0.89% | $284.54M | 1.57% | Jun 30, 2026 |
| Fidelity Contrafund K6 | 1,075,723 | 0.73% | $232.42M | 0.62% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 1,042,998 | 0.71% | $225.35M | 0.56% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,037,164 | 0.70% | $224.09M | 2.47% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Christopher Viehbacher | President and CEO, Director | 21,095 | 0.01% | Feb 17, 2026 |
| Michael Parini | Chief Legal Officer | – | – | Sep 3, 2026 |
| Adam Keeney | Head of Corporate Development | 6,365 | 0.00% | May 5, 2026 |
| Sean Godbout | Chief Accounting Officer | 1,396 | 0.00% | Apr 3, 2026 |
| Robin Kramer | Chief Financial Officer | 9,024 | 0.01% | Feb 17, 2026 |
| Susan H. Alexander | EVP Chief Legal Officer | 58,537 | 0.04% | Feb 17, 2026 |
| Ginger Gregory | EVP, Human Resources | 22,359 | 0.02% | Feb 17, 2026 |
| Priya Singhal | Head of Development | 8,043 | 0.01% | Feb 17, 2026 |
| Rachid Izzar | Head of Global Product Strat. | 11,786 | 0.01% | Feb 17, 2026 |
| Nicole Murphy | Head of Pharm Ops and Tech | 19,611 | 0.01% | Feb 17, 2026 |
| Jane Grogan | Head of Research | 3,176 | 0.00% | Feb 17, 2026 |
| Michael R. McDonnell | EVP, Chief Financial Officer | 24,341 | 0.02% | Feb 12, 2025 |
| Lloyd Minor | Director | 2,689 | 0.00% | Aug 5, 2026 |
| Monish D. Patolawala | Director | 5,215 | 0.00% | Jun 11, 2026 |
| Jesus B. Mantas | Director | 11,263 | 0.01% | Jun 11, 2026 |
| Stephen A. Sherwin | Director | 15,193 | 0.01% | Jun 11, 2026 |
| William A. Hawkins | Director | 10,365 | 0.01% | Jun 11, 2026 |
| Menelas N. Pangalos | Director | 3,875 | 0.00% | Jun 11, 2026 |
| Eric K. Rowinsky | Director | 25,844 | 0.02% | Jun 11, 2026 |
| Maria C. Freire | Director | 8,820 | 0.01% | Jun 11, 2026 |
| Susan Langer | Director | 6,634 | 0.00% | Jun 11, 2026 |
| Caroline Dorsa | Director | 31,002 | 0.02% | Jun 18, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Lloyd Minor Director | Aug 4, 2026 | Sale(10b5-1 plan) | −593 | $200.96 | $119.17K | 2,689 |
| Lloyd Minor Director | Aug 3, 2026 | Sale(10b5-1 plan) | −593 | $203.34 | $120.58K | 3,282 |
| Maria C. Freire Director | Jun 9, 2026 | Award | +2,005 | – | – | 8,820 |
| Stephen A. Sherwin Director | Jun 9, 2026 | Award | +1,505 | – | – | 15,193 |
| Monish D. Patolawala Director | Jun 9, 2026 | Award | +1,505 | – | – | 5,215 |
| Jesus B. Mantas Director | Jun 9, 2026 | Award | +1,505 | – | – | 11,263 |
| Susan Langer Director | Jun 9, 2026 | Award | +1,505 | – | – | 6,634 |
| Lloyd Minor Director | Jun 9, 2026 | Award | +1,505 | – | – | 3,875 |
| Eric K. Rowinsky Director | Jun 9, 2026 | Award | +1,505 | – | – | 25,844 |
| Menelas N. Pangalos Director | Jun 9, 2026 | Award | +1,505 | – | – | 3,875 |
| Menelas N. Pangalos Director | Jun 9, 2026 | Option exercise | +2,370 | – | – | 2,370 |
| William A. Hawkins Director | Jun 9, 2026 | Award | +1,505 | – | – | 10,365 |
| Adam Keeney Head of Corporate Development | May 1, 2026 | Tax withholding | −455 | $187.06 | $85.11K | 6,365 |
| Adam Keeney Head of Corporate Development | May 1, 2026 | Option exercise | +939 | – | – | 6,820 |
| Sean Godbout Chief Accounting Officer | Apr 1, 2026 | Option exercise | +181 | – | – | 1,396 |
| Sean Godbout Chief Accounting Officer | Apr 1, 2026 | Tax withholding | −54 | $183.78 | $9.92K | 1,342 |
| Nicole Murphy Head of Pharm Ops and Tech | Feb 12, 2026 | Buy | +3 | $195.04 | $585 | 19,611 |
| Priya Singhal Head of Development | Feb 9, 2026 | Sale(10b5-1 plan) | −2,660 | $199.83 | $531.55K | 8,043 |
| Christopher Viehbacher President and CEO, Director | Feb 6, 2026 | Tax withholding | −4,356 | $201.18 | $876.34K | 21,095 |
| Christopher Viehbacher President and CEO, Director | Feb 6, 2026 | Option exercise | +15,453 | – | – | 36,548 |
| Christopher Viehbacher President and CEO, Director | Feb 6, 2026 | Tax withholding | −6,624 | $201.18 | $1.33M | 29,924 |
| Christopher Viehbacher President and CEO, Director | Feb 6, 2026 | Option exercise | +9,008 | – | – | 25,451 |
| Nicole Murphy Head of Pharm Ops and Tech | Feb 6, 2026 | Option exercise | +4,683 | – | – | 21,016 |
| Nicole Murphy Head of Pharm Ops and Tech | Feb 6, 2026 | Option exercise | +2,102 | – | – | 16,324 |
| Nicole Murphy Head of Pharm Ops and Tech | Feb 6, 2026 | Tax withholding | −1,017 | $201.18 | $204.60K | 15,307 |
| Nicole Murphy Head of Pharm Ops and Tech | Feb 6, 2026 | Option exercise | +1,940 | – | – | 17,247 |
| Nicole Murphy Head of Pharm Ops and Tech | Feb 6, 2026 | Tax withholding | −914 | $201.18 | $183.88K | 16,333 |
| Nicole Murphy Head of Pharm Ops and Tech | Feb 6, 2026 | Tax withholding | −1,408 | $201.18 | $283.26K | 19,608 |
| Jane Grogan Head of Research | Feb 6, 2026 | Option exercise | +1,385 | – | – | 3,176 |
| Jane Grogan Head of Research | Feb 6, 2026 | Tax withholding | −407 | $201.18 | $81.88K | 2,769 |
| Jane Grogan Head of Research | Feb 6, 2026 | Option exercise | +1,873 | – | – | 4,642 |
| Jane Grogan Head of Research | Feb 6, 2026 | Tax withholding | −584 | $201.18 | $117.49K | 4,058 |
| Susan H. Alexander EVP Chief Legal Officer | Feb 6, 2026 | Option exercise | +2,190 | – | – | 38,455 |
| Susan H. Alexander EVP Chief Legal Officer | Feb 6, 2026 | Tax withholding | −1,059 | $201.18 | $213.05K | 37,396 |
| Susan H. Alexander EVP Chief Legal Officer | Feb 6, 2026 | Option exercise | +1,940 | – | – | 39,336 |
| Susan H. Alexander EVP Chief Legal Officer | Feb 6, 2026 | Tax withholding | −931 | $201.18 | $187.30K | 38,405 |
| Susan H. Alexander EVP Chief Legal Officer | Feb 6, 2026 | Tax withholding | −1,514 | $201.18 | $304.59K | 41,807 |
| Susan H. Alexander EVP Chief Legal Officer | Feb 6, 2026 | Option exercise | +4,916 | – | – | 43,321 |
| Adam Keeney Head of Corporate Development | Feb 6, 2026 | Tax withholding | −589 | $201.18 | $118.50K | 3,597 |
| Adam Keeney Head of Corporate Development | Feb 6, 2026 | Option exercise | +1,802 | – | – | 4,186 |
| Adam Keeney Head of Corporate Development | Feb 6, 2026 | Option exercise | +3,278 | – | – | 6,875 |
| Adam Keeney Head of Corporate Development | Feb 6, 2026 | Tax withholding | −994 | $201.18 | $199.97K | 5,881 |
| Robin Kramer Chief Financial Officer | Feb 6, 2026 | Tax withholding | −207 | $201.18 | $41.64K | 9,024 |
| Robin Kramer Chief Financial Officer | Feb 6, 2026 | Option exercise | +789 | – | – | 8,801 |
| Robin Kramer Chief Financial Officer | Feb 6, 2026 | Tax withholding | −273 | $201.18 | $54.92K | 8,528 |
| Robin Kramer Chief Financial Officer | Feb 6, 2026 | Tax withholding | −1,063 | $201.18 | $213.85K | 11,472 |
| Robin Kramer Chief Financial Officer | Feb 6, 2026 | Option exercise | +3,511 | – | – | 12,535 |
| Robin Kramer Chief Financial Officer | Feb 6, 2026 | Option exercise | +703 | – | – | 9,231 |
| Priya Singhal Head of Development | Feb 6, 2026 | Tax withholding | −1,056 | $201.18 | $212.45K | 7,432 |
| Priya Singhal Head of Development | Feb 6, 2026 | Option exercise | +4,683 | – | – | 12,115 |
| Priya Singhal Head of Development | Feb 6, 2026 | Tax withholding | −1,412 | $201.18 | $284.07K | 10,703 |
| Priya Singhal Head of Development | Feb 6, 2026 | Option exercise | +2,217 | – | – | 8,488 |
| Ginger Gregory EVP, Human Resources | Feb 6, 2026 | Tax withholding | −1,132 | $201.18 | $227.74K | 22,359 |
| Ginger Gregory EVP, Human Resources | Feb 6, 2026 | Tax withholding | −666 | $201.18 | $133.99K | 19,745 |
| Ginger Gregory EVP, Human Resources | Feb 6, 2026 | Option exercise | +1,802 | – | – | 20,411 |
| Ginger Gregory EVP, Human Resources | Feb 6, 2026 | Tax withholding | −791 | $201.18 | $159.13K | 18,609 |
| Ginger Gregory EVP, Human Resources | Feb 6, 2026 | Option exercise | +1,635 | – | – | 19,400 |
| Ginger Gregory EVP, Human Resources | Feb 6, 2026 | Option exercise | +3,746 | – | – | 23,491 |
| Rachid Izzar Head of Global Product Strat. | Feb 6, 2026 | Option exercise | +3,043 | – | – | 11,786 |
| Rachid Izzar Head of Global Product Strat. | Feb 6, 2026 | Tax withholding | −775 | $201.18 | $155.91K | 11,011 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Lloyd Minor Director | Aug 4, 2026 | 593 | $119.17K | Aug 4, 2026 | Restricted Stock Vesting |
| Lloyd Minor Director | Aug 3, 2026 | 593 | $120.58K | Aug 3, 2026 | Restricted Stock Vesting |
| Priya Singhal Officer | Feb 9, 2026 | 2,660 | $531.55K | Feb 9, 2026 | Restricted Stock Vesting |
| Priya Singhal Officer | Feb 2, 2026 | 748 | $134.12K | Feb 2, 2026 | Restricted Stock Vesting |
| Priya Singhal Officer | Sep 2, 2025 | 517 | $69.05K | Sep 2, 2025 | Restricted Stock Vesting |
| Rachid Izzar Officer | Jul 8, 2025 | 2,223 | $300.11K | Jul 8, 2025 | Restricted Stock Vesting |
| Priya Singhal Officer | May 19, 2025 | 3,806 | $480.51K | May 19, 2025 | Restricted Stock Vesting |
| A. Sherwin Stephen Director | Mar 7, 2025 | 8,760 | $1.29M | Mar 7, 2025 | Restricted Stock Units |
| Priya Singhal Officer | Dec 9, 2024 | 110 | $17.29K | Dec 9, 2024 | Restricted Stock Vesting |
| Priya Singhal Officer | Sep 3, 2024 | 431 | $88.02K | Sep 3, 2024 | Restricted Stock Vesting |
| Priya Singhal Officer | Apr 2, 2024 | 93 | $19.82K | Apr 2, 2024 | ESPP Purchase |
| Priya Singhal Officer | Feb 22, 2024 | 262 | $57.96K | Feb 22, 2024 | Performance Shares |
| Priya Singhal Officer | Feb 21, 2024 | 108 | $23.92K | Feb 21, 2024 | Performance Shares |
| Priya Singhal Officer | Feb 12, 2024 | 419 | $100.33K | Feb 12, 2024 | Restricted Stock Vesting |
| Priya Singhal Officer | Feb 2, 2024 | 634 | $155.92K | Feb 2, 2024 | Restricted Stock Vesting |